Anzeige
Mehr »
Freitag, 18.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EFY | ISIN: US7665597024 | Ticker-Symbol: RI2
Frankfurt
17.07.25 | 15:56
16,400 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
RIGEL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RIGEL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,10016,50017.07.
16,00016,60017.07.

Aktuelle News zur RIGEL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.07.H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL)2
07.07.Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)58SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant...
► Artikel lesen
RIGEL PHARMACEUTICALS Aktie jetzt für 0€ handeln
10.06.High-Grade Pollucite Confirmed as Main Caesium Host Mineral at the Vega and Rigel Zones1
23.05.RIGEL PHARMACEUTICALS INC - 8-K, Current Report3
07.05.Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance8
06.05.RIGEL PHARMACEUTICALS INC - 8-K, Current Report-
06.05.RIGEL PHARMACEUTICALS INC - 10-Q, Quarterly Report1
06.05.Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business Update290First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of...
► Artikel lesen
05.05.A Preview Of Rigel Pharmaceuticals' Earnings1
04.04.Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)121SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant...
► Artikel lesen
27.03.Rigel settles patent litigation regarding its immune thrombocytopenia treatment4
27.03.Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma389WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) Thursday announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA...
► Artikel lesen
27.03.RIGEL PHARMACEUTICALS INC - 8-K, Current Report4
27.03.Rigel settles patent litigation over TAVALISSE treatment2
10.03.Rigel Pharmaceuticals erweitert Vorstand um Onkologie-Experten1
10.03.Rigel Pharmaceuticals adds oncology expert to board2
06.03.Citi lifts Rigel stock price target to $55, maintains Buy rating3
06.03.Al Seer Marine completes first stage of expansion with delivery of Tabit and Rigel MR tankers1
05.03.Cantor Fitzgerald maintains Rigel stock Neutral with $20 target12
05.03.Rigel Pharmaceuticals stock holds Buy rating, $57 target11
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1